


Ask a doctor about a prescription for ROPIVACAINE KABI 10 mg/ml INJECTABLE SOLUTION
Package Leaflet: Information for the User
Ropivacaína Kabi 10 mg/ml solution for injection EFG
Ropivacaína, hydrochloride
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
The name of this medicine is “Ropivacaína Kabi 10 mg/ml solution for injection EFG”, but in the rest of this leaflet it will be referred to as “Ropivacaína Kabi”.
Contents of the pack:
Ropivacaína Kabi 10 mg/ml solution for injection is indicated in adults and adolescents over 12 years to numb (anesthetize) specific parts of the body during surgery.
You will not be given Ropivacaína Kabi
If you are not sure if any of the above applies to you, talk to your doctor before you are given Ropivacaína Kabi.
Warnings and precautions
Special care should be taken to avoid any injectionof Ropivacaína Kabi directly into the bloodstreamto prevent any immediate toxic effect. It should not be injected into inflamed areas.
Tell your doctor, nurse or any other healthcare professional before you are given Ropivacaína Kabi:
Tell your doctor if you have any of these problems, as it may be necessary to adjust the dose of Ropivacaína Kabi.
Tell your doctor, nurse or any other healthcare professional before you are given Ropivacaína Kabi:
Tell your doctor if you or a family member has porphyria, as it may be necessary to use another anesthetic.
Tell your doctor about any illness or medical condition you have before starting treatment.
Children
Special care should be taken:
Using Ropivacaína Kabi with other medicines
Tell your doctor or healthcare professional that you are using, have recently used or may need to use any other medicine. This is because Ropivacaína Kabi can affect how some medicines work, and other medicines can affect Ropivacaína Kabi.
In particular, tell your doctor if you are using any of the following medicines:
Your doctor needs to know this to calculate the correct dose of Ropivacaína Kabi to give you.
Also, tell your doctor if you are using any of the following medicines:
This is because your body takes longer to eliminate Ropivacaína Kabi if you are using these medicines. If you are using any of these medicines, prolonged use of Ropivacaína Kabi should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or plan to become pregnant, talk to your doctor before you are given this medicine.
It is not known if ropivacaína affects pregnancy or if it passes into breast milk.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Ropivacaína Kabi can cause drowsiness and affect your reaction speed. Do not drive or use tools or machines after taking Ropivacaína Kabi, until the next day.
Ropivacaína Kabi contains sodium chloride
This medicine contains 2.8 mg of sodium (main component of table/cooking salt) per milliliter. This is equivalent to 0.14% of the maximum daily sodium intake recommended for an adult.
Ropivacaína Kabi will be given to you by a doctor. The dose your doctor gives you will depend on the type of pain relief you need. It will also depend on your size, age, and physical condition.
Ropivacaína Kabi will be given to you as an injection. The part of the body where it will be used will depend on why you are being given Ropivacaína Kabi. Your doctor will give you Ropivacaína Kabi in one of the following places:
When Ropivacaína Kabi is used in one of these ways, it prevents nerves from sending pain messages to the brain. It prevents you from feeling pain, heat, or cold where it is used, however, you may still have other sensations such as pressure or touch.
Your doctor knows the correct way to give you this medicine.
Dosage
The dose used will depend on why you are being given the medicine and your health, age, and weight.
Duration of treatment
The administration of ropivacaína usually lasts between 2 and 10 hoursin the case of anesthesiaprior to certain surgical operations and up to 72 hoursin the case of pain reliefduring and after surgery.
If you are given more Ropivacaína Kabi than you should
Severe side effects due to the administration of more Ropivacaína Kabi than necessary require special treatment and the doctor treating you is prepared to handle these situations.
The first signs that you have been given too much Ropivacaína Kabi are usually the following:
These symptoms can precede cardiac arrest, respiratory arrest, or severe convulsions.
To reduce the risk of severe side effects, your doctor will stop the administration of Ropivacaína Kabi as soon as these signs appear. This means that if any of these signs occur to you, or if you think you may have received too much Ropivacaína Kabi, tell your doctor or healthcare professional immediately.
More severe side effects from taking too much Ropivacaína Kabi include problems with speech, muscle stiffness, tremors, agitation, seizures, and loss of consciousness.
Tell your doctor or healthcare professional if you notice any of the above symptoms.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Important side effects to look out for:
Sudden allergic reactionsthat can be life-threatening(such as anaphylaxis, including anaphylactic shock) are rare, as they affect between 1 and 10 patients in every 10,000. Possible symptoms include:
If you think you are having an allergic reaction to Ropivacaína Kabi, tell your doctor or healthcare professional immediately.
Other possible side effects:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from the available data):
Other possible side effects include:
Possible side effects detected with other local anesthetics that may also be caused by Ropivacaína Kabi include:
Children
In children, the side effects are the same as in adults, except for low blood pressure, which occurs less frequently in children (affecting between 1 and 10 children in every 100) and general discomfort, which occurs more frequently in children (affecting more than 1 in 10).
Reporting of side effects:
If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
This medicine does not require special storage conditions.
Keep out of sight and reach of children.
Do not use this medicine after the expiry date stated on the blister, ampoule, or carton. The expiry date is the last day of the month stated.
Do not use this medicine if you notice a precipitate in the injection solution.
Normally, your doctor or hospital will store Ropivacaína Kabi and are responsible for the quality of the product once opened if it is not used immediately. They are also responsible for disposing of any unused Ropivacaína Kabi properly.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Ropivacaína Kabi
Each 20 ml polypropylene ampoule contains 200 mg of ropivacaine (hydrochloride).
Appearance of the product and container contents
Ropivacaína Kabi injectable solution is a clear and colorless solution for injection.
Ropivacaína Kabi 10 mg/ml injectable solution is available in 10 ml and 20 ml transparent polypropylene ampoules.
Package sizes:
1, 5, and 10 ampoule(s)
1, 5, and 10 ampoule(s) in blister packaging
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Fresenius Kabi España S.A.U.
C/ Marina 16-18
08005 Barcelona
Manufacturer
HP Halden Pharma AS
Svinesundsveien 80
1788 Halden
Norway
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Netherlands | Ropivacaïne Fresenius Kabi 10 mg/ml solution for injection |
Austria | Ropivacainhydrochlorid Kabi 10 mg/ml Injektionslösung |
Belgium | Ropivacaïne Fresenius Kabi 10 mg/ml solution for injection/solution injectable/Injektionslösung |
Cyprus | Ropivacaine Kabi 10 mg/ml, solution for injection |
Germany | Ropivacainhydrochlorid Kabi 10 mg/ml Injektionslösung |
Denmark | Ropivacaine Fresenius Kabi, injection solution, 10 mg/ml |
Estonia | Ropivacaine Kabi |
Greece | Ropivacaine Kabi 10 mg/ml, solution for injection |
Spain | Ropivacaine Kabi 10 mg/ml injectable solution EFG |
Finland | Ropivacain Fresenius Kabi 10 mg/ml injection solution, liquid |
France | Ropivacaïne Kabi 10 mg/ml, solution injectable |
Hungary | Ropivacaine Fresenius Kabi 10 mg/ml solution for injection |
Italy | Ropivacaina Kabi |
Latvia | Ropivacaine Kabi 10 mg/ml solution for injection |
Lithuania | Ropivacaine hydrochloride Kabi 10 mg/ml injection solution |
Luxembourg | Ropivacaïne Fresenius Kabi 10 mg/ml Injektionslösung |
Malta | Ropivacaine Kabi 10 mg/ml |
Norway | Ropivacain Fresenius Kabi 10 mg/ml injection solution, liquid |
Poland | Ropivacaine Kabi |
Portugal | Ropivacaína Kabi |
Romania | Ropivacaine Kabi 10 mg/ml injectable solution |
Slovenia | Ropivakainijev klorid Kabi 10 mg/ml solution for injection |
Sweden | Ropivacain Fresenius Kabi 10 mg/ml, injection solution, liquid |
United Kingdom (Northern Ireland) | Ropivacaine 10 mg/ml solution for injection |
Date of the last revision of this leaflet: November 2024
“Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)http://www.aemps.gob.es/”
------------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Handling
Ropivacaína Kabi should only be used by, or under the supervision of, clinical personnel with experience in regional anesthesia (see section 3).
Shelf life after opening
Use immediately.
Ropivacaína Kabi products are intended for single use. Discard any unused solution.
The medicinal product should be visually inspected before use. The solution should only be used if it is clear, practically free of particles, and if the container is not damaged.
The intact container should not be re-autoclaved.
Incompatibilities
In the absence of compatibility studies, this medicinal product should not be mixed with others.
Precipitation may occur in alkaline solutions, as ropivacaine shows poor solubility at pH > 6.0.
Disposal
Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ROPIVACAINE KABI 10 mg/ml INJECTABLE SOLUTION – subject to medical assessment and local rules.